雷珠单抗按需治疗对糖尿病视网膜病变改善的持久性:RIDE和RISE开放标签扩展研究
该研究汇总分析RIDE和RISE开放标签扩展(OLE)中500例糖尿病视网膜病变(DR)合并糖尿病黄斑水肿(DME)患者,评估从每月雷珠单抗改为个体化按需(PRN)治疗后DR改善的持久性。结果显示超过70%的OLE患者DR严重度改善得以维持,但约三分之一患者出现DR恶化,提示长期管理中需密切监测。
要点
- OLE中24%(121/500)患者无需额外雷珠单抗注射。
- 无需再治疗者57%–78%DR稳定,0%–7%改善≥2步,22%–36%恶化≥2步。
- 需再治疗者84%–94%DR稳定,2%改善≥2步,3%–14%恶化≥2步。
核心结论
- 从每月雷珠单抗改为个体化0.5 mg PRN方案后,超过70%的OLE患者DR严重度改善得以维持。
- 约三分之一OLE患者出现DR恶化,长期管理应包含仔细监测。
研究设计与样本
- RIDE和RISE开放标签扩展(OLE)的汇总分析,纳入完成36个月核心研究的DR合并DME患者。
- 核心研究中759例患者随机1:1:1接受雷珠单抗0.3 mg每月、0.5 mg每月或假注射每月,24个月后假注射组交叉至雷珠单抗0.5 mg每月。
- OLE中500例患者可根据预设DME再治疗标准接受雷珠单抗0.5 mg PRN。
主要发现
- 进入OLE的500例患者中121例(24%)无需额外雷珠单抗注射。
- 367例在36和48个月有可评估DR,其中无需再治疗者88/367,需再治疗者279/367。
- 无需再治疗者中57%–78%DR稳定、0%–7%改善≥2步、22%–36%恶化≥2步。
- 需再治疗者中84%–94%DR稳定、2%改善≥2步、3%–14%恶化≥2步。
- OLE期间平均视力改善得以维持,与DR严重度变化无关。
关键数值与推荐
- OLE中雷珠单抗0.5 mg PRN依据预设DME再治疗标准给药。
- DR严重度采用早期治疗糖尿病视网膜病变研究(ETDRS)DR严重度量表通过照相评估。
临床怎么用
- 对DR合并DME患者,从每月雷珠单抗转换为个体化0.5 mg PRN方案后多数DR改善可维持。
- 因约三分之一患者可能出现DR恶化,长期管理中应进行仔细监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the durability of diabetic retinopathy (DR) improvements after a change in ranibizumab dosing from monthly to individualized pro re nata (PRN) therapy. DESIGN: Pooled analysis of the open-label extension (OLE) of RIDE and RISE (clinicaltrials.gov identifiers, NCT00473382 and NCT00473330) patients with DR and diabetic macular edema (DME). PARTICIPANTS: Patients who completed 36-month participation in RIDE and RISE and entered the OLE. METHODS: In RIDE and RISE, patients (n = 759) were randomized 1:1:1 to ranibizumab 0.3 mg monthly, 0.5 mg monthly, or monthly sham injections with rescue macular laser available after 6 months, per protocol-specified criteria. After 24 months, sham patients crossed over to ranibizumab 0.5 mg monthly. After 36 months in the core studies, patients in the OLE (n = 500) could receive ranibizumab 0.5 mg PRN based on predefined DME re-treatment criteria. Diabetic retinopathy severity was evaluated photographically using the Early Treatment Diabetic Retinopathy Study DR severity scale. MAIN OUTCOME MEASURES: Change in DR severity from months 36 to 48 by re-treatment status. RESULTS: Among patients who entered the OLE, 121 of 500 (24%) did not require additional ranibizumab injections. Overall, 367 patients had evaluable DR at months 36 and 48. Among patients not requiring ranibizumab re-treatment from months 36 to 48 (88/367), 57% to 78%, 0% to 7%, and 22% to 36% experienced DR severity stability, 2-step or more improvement, and 2-step or more worsening, respectively. Among patients requiring ranibizumab re-treatment (279/367), 84% to 94%, 2%, and 3% to 14% experienced DR severity stability, 2-step or more improvement, and 2-step or more worsening, respectively. On average, vision improvements were maintained during the OLE regardless of change in DR severity. CONCLUSIONS: Diabetic retinopathy severity improvements with ranibizumab were maintained in over 70% of OLE patients after switching from ranibizumab monthly to an individualized ranibizumab 0.5 mg PRN dosing regimen. Because approximately one third of OLE patients experienced DR worsening, careful monitoring should be part of the long-term management of patients with DR.
引用
- Sun JK, Wang PW, Taylor S, et al. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. Ophthalmology. 2018. PMID: 30419298. doi:10.1016/j.ophtha.2018.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。